Cash Flow Statement (Annual)

TGTX / TG Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities Continuing Operations
  Profit Loss -889 -26,183 -20,478 -55,781 -62,949 -78,253 -118,476
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation 86 3,422 5,203 21,105 15,697 7,510 15,945
    Noncash Licensing Expense - - - - - - -
    Depreciation 0 0 1 4 15 63 82
    Investment Income Amortization Of Premium - 0 1 194 536 459 61
    Change In Fair Value Of Notes Payable 0 -816 2,415 -211 57 110 -59
  Increase Decrease In Operating Capital
    Increase Decrease In Other Current Assets -4 1,933 -229 4,563 3,106 -3,564 2,665
    Increase Decrease In Prepaid Rent - - - - - - -
    Increase Decrease In Accrued Interest Receivable Net - 0 27 58 101 -102 25
    Increase Decrease In Other Noncurrent Assets - 0 85 0 42 5 -162
    Increase Decrease In Other Accounts Payable And Accrued Liabilities 408 596 4,035 -603 5,471 6,493 11,020
    Increase Decrease In Deferred Rent - - - - - - -
    Increase Decrease In Deferred Revenue 0 1,981 -152 -152 -152 -152 -152
    Net Cash Provided By Used In Operating Activities Continuing Operations - -5,188 -10,824 -35,060 -44,690 -61,591 -93,764
Net Cash Provided By Used In Investing Activities Continuing Operations
  Payments To Acquire Property Plant And Equipment 0 1 6 19 42 344 2
  Payments To Acquire Held To Maturity Securities Short Term - - 4,920 18,337 48,994 15,200 28,006
  Proceeds From Maturities - - 0 0 24,350 29,500 19,800
  Net Cash Provided By Used In Investing Activities Continuing Operations - -1 -4,926 -18,355 -24,686 26,545 -8,208
Net Cash Provided By Used In Financing Activities Continuing Operations
  Proceeds From Warrant Exercises - 0 2,281 3,557 1,067 618 2,143
  Net Proceeds From Shares New Issues Overallotments - - 37,648 65,614 67,761 4,411 131,516
  Net Cash Provided By Used In Financing Activities Continuing Operations - 11,897 39,779 68,644 68,724 5,016 133,659
  Cash And Cash Equivalents Period Increase Decrease 9,748 6,708 24,029 15,228 -652 -30,030 31,687
Cash And Cash Equivalents Period Increase Decrease
  Cash And Cash Equivalents At Carrying Value 9,748 16,456 40,485 55,714 55,061 25,031 56,718
  Restricted Cash - - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - -
Nonmonetary Transactions
  Accrued Financing Costs 61 0 0 - - - -
  Reclassification Of Deferred Financing Costs Toadditional Paidin Capital - - - - - - -

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Your Daily Pharma Scoop: TGTX Positive Data In MS, Iovance Trial Delay

2018-10-12 seekingalpha
After its initial hiccup earlier with its CLL drug, this news should bolster the stock a little. (7-0)

Major Biopharma Catalysts to Watch For in October

2018-10-06 247wallst
Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-7)

Major Biopharma Catalysts on October’s FDA Calendar

2018-09-29 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which can spell disaster for a stock, comes great reward as well. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-18)

Tyme Technologies (TYME) Shares March Higher, Can It Continue?

2018-09-28 zacks
As of late, it has definitely been a great time to be an investor in Tyme Technologies, Inc. (TYME - Free Report) . The stock has moved higher by 22.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. (16-0)

Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?

2018-09-28 zacks
Ra Pharmaceuticals, Inc. (RARX - Free Report) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue? (16-0)

CUSIP: 88322Q108